LIVIVO - Search results -

Search results

Result 1 - 10 of total 13

Search options

Article ; Online: Impact of a Pharmacist-Managed Outpatient Parenteral Antimicrobial Therapy (OPAT) Service on Cost Savings and Clinical Outcomes at an Academic Medical Center - ADDENDUM.

Epperson, Taylor M / Bennett, Kiya K / Kupiec, Katherine K / Speigel, Kathy / Neely, Stephen B / Resman-Targoff, Beth H / Kinney, Karen K / White, Bryan P

Antimicrobial stewardship & healthcare epidemiology : ASHE

2023 Volume 3, Issue 1, Page(s) e240

Language	English
Publishing date	2023-12-18
Publishing country	England
Document type	Journal Article ; Published Erratum
ISSN	2732-494X
ISSN (online)	2732-494X
DOI	10.1017/ash.2023.524
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Impact of a Pharmacist-Managed Outpatient Parenteral Antimicrobial Therapy (OPAT) Service on Cost Savings and Clinical Outcomes at an Academic Medical Center.

Epperson, Taylor M / Bennett, Kiya K / Kupiec, Katherine K / Speigel, Kathy / Neely, Stephen B / Resman-Targoff, Beth H / Kinney, Karen K / White, Bryan P

Antimicrobial stewardship & healthcare epidemiology : ASHE

2023 Volume 3, Issue 1, Page(s) e15

Abstract: Background: Outpatient antimicrobial therapy (OPAT) is managed by a variety of teams, but primarily through an infectious disease clinic. At our medical center, OPAT monitoring is performed telephonically by pharmacists through a collaborative practice ... ...

Abstract	Background: Outpatient antimicrobial therapy (OPAT) is managed by a variety of teams, but primarily through an infectious disease clinic. At our medical center, OPAT monitoring is performed telephonically by pharmacists through a collaborative practice agreement under the supervision of an infectious disease physician. The effect of telephonic monitoring of OPAT by pharmacists on patient outcomes is unknown. Methods: This retrospective cohort study was conducted between July 2017 and July 2018 at a 350-bed academic medical center and included adult patients discharged home on IV antibiotics or oral linezolid. The experimental group comprised patients discharged with a consultation for the OPAT management program, whereas the control group comprised patients discharged home without a consultation. The primary outcome was 30-day readmission. Results: In total, 399 patients were included: 243 patients in the OPAT management program group and 156 patients in the control group. The 30-day readmission rates were similar in each cohort (20% vs 19%; Conclusions: We did not find a difference in 30-day readmissions between patients receiving pharmacy-driven OPAT management services and those who did not. Patients receiving vancomycin via OPAT had lower 30-day readmissions when included in the pharmacist-driven OPAT management program. Institutions with limited resources may consider reserving OPAT management services for patients receiving antimicrobials that require pharmacokinetic dosing and/or close monitoring.
Language	English
Publishing date	2023-01-17
Publishing country	England
Document type	Journal Article
ISSN	2732-494X
ISSN (online)	2732-494X
DOI	10.1017/ash.2022.374
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Impact of a Pharmacist-Managed Outpatient Parenteral Antimicrobial Therapy (OPAT) Service on Cost Savings and Clinical Outcomes at an Academic Medical Center – ADDENDUM

Taylor M. Epperson / Kiya K. Bennett / Katherine K. Kupiec / Kathy Speigel / Stephen B. Neely / Beth H. Resman-Targoff / Karen K. Kinney / Bryan P. White

Antimicrobial Stewardship & Healthcare Epidemiology, Vol

2023 Volume 3

Keywords	Infectious and parasitic diseases ; RC109-216 ; Public aspects of medicine ; RA1-1270
Language	English
Publishing date	2023-01-01T00:00:00Z
Publisher	Cambridge University Press
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Impact of a Pharmacist-Managed Outpatient Parenteral Antimicrobial Therapy (OPAT) Service on Cost Savings and Clinical Outcomes at an Academic Medical Center

Taylor M. Epperson / Kiya K. Bennett / Katherine K. Kupiec / Kathy Speigel / Stephen B. Neely / Beth H. Resman-Targoff / Karen K. Kinney / Bryan P. White

Antimicrobial Stewardship & Healthcare Epidemiology, Vol

2023 Volume 3

Abstract: Abstract Background: Outpatient antimicrobial therapy (OPAT) is managed by a variety of teams, but primarily through an infectious disease clinic. At our medical center, OPAT monitoring is performed telephonically by pharmacists through a collaborative ... ...

Abstract	Abstract Background: Outpatient antimicrobial therapy (OPAT) is managed by a variety of teams, but primarily through an infectious disease clinic. At our medical center, OPAT monitoring is performed telephonically by pharmacists through a collaborative practice agreement under the supervision of an infectious disease physician. The effect of telephonic monitoring of OPAT by pharmacists on patient outcomes is unknown. Methods: This retrospective cohort study was conducted between July 2017 and July 2018 at a 350-bed academic medical center and included adult patients discharged home on IV antibiotics or oral linezolid. The experimental group comprised patients discharged with a consultation for the OPAT management program, whereas the control group comprised patients discharged home without a consultation. The primary outcome was 30-day readmission. Results: In total, 399 patients were included: 243 patients in the OPAT management program group and 156 patients in the control group. The 30-day readmission rates were similar in each cohort (20% vs 19%; P = .8193); however, the 30-day readmission rates were lower in the OPAT management program for patients discharged on vancomycin (19.4% vs 39.1%; P = .004). Conclusions: We did not find a difference in 30-day readmissions between patients receiving pharmacy-driven OPAT management services and those who did not. Patients receiving vancomycin via OPAT had lower 30-day readmissions when included in the pharmacist-driven OPAT management program. Institutions with limited resources may consider reserving OPAT management services for patients receiving antimicrobials that require pharmacokinetic dosing and/or close monitoring.
Keywords	Infectious and parasitic diseases ; RC109-216 ; Public aspects of medicine ; RA1-1270
Subject code	610
Language	English
Publishing date	2023-01-01T00:00:00Z
Publisher	Cambridge University Press
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Medical therapy: where are we now?

Resman-Targoff, Beth H

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

2006 Volume 63, Issue 18 Suppl 4, Page(s) S11–8

Abstract: Purpose: This article reviews the mechanisms of action, safety, and efficacy of the nonbiologic, or traditional, disease-modifying antirheumatic drugs (DMARDs), particularly methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine. It also ... ...

Abstract	Purpose: This article reviews the mechanisms of action, safety, and efficacy of the nonbiologic, or traditional, disease-modifying antirheumatic drugs (DMARDs), particularly methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine. It also addresses various aspects of rheumatoid arthritis (RA) clinical trials that warrant careful interpretation, including response criteria, outcomes measurements, study designs, and results of combination therapy trials. Summary: The considerable progress in the treatment of RA over the past 20 years is due in large part to a better understanding of how to use DMARDs optimally and the introduction of biologic agents. In addition to their ability to suppress inflammation, and thereby reduce symptoms of pain and stiffness, these drugs also have the potential to alter the course of RA by slowing disease progression and reducing joint damage. Conclusion: Studies have demonstrated that early treatment of RA and rapid suppression of inflammation are extremely important as they provide long-term benefits and improve the overall prognosis for patients with the disease.
MeSH term(s)	Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Drug Therapy, Combination ; Humans ; Hydroxychloroquine/adverse effects ; Hydroxychloroquine/therapeutic use ; Isoxazoles/adverse effects ; Isoxazoles/therapeutic use ; Leflunomide ; Methotrexate/adverse effects ; Methotrexate/therapeutic use ; Sulfasalazine/adverse effects ; Sulfasalazine/therapeutic use ; Treatment Outcome
Chemical Substances	Antirheumatic Agents ; Isoxazoles ; Sulfasalazine (3XC8GUZ6CB) ; Hydroxychloroquine (4QWG6N8QKH) ; Leflunomide (G162GK9U4W) ; Methotrexate (YL5FZ2Y5U1)
Language	English
Publishing date	2006-09-05
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	1224627-x
ISSN	1079-2082
ISSN	1079-2082
DOI	10.2146/ajhp060363
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 419: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Daptomycin dosing in obese patients: analysis of the use of adjusted body weight

Fox, Ashley N / Smith, Winter J / Kupiec, Katherine E / Harding, Stephanie J / Resman-Targoff, Beth H / Neely, Stephen B / White, Bryan P / Owens, Ryan E

Therapeutic advances in infectious disease

2019 Volume 6, Page(s) 2049936118820230

Abstract: Background: Food and Drug Administration-approved daptomycin dosing uses actual body weight, despite limited dosing information for obese patients. Studies report alterations in daptomycin pharmacokinetics and creatine phosphokinase elevations ... ...

Abstract	Background: Food and Drug Administration-approved daptomycin dosing uses actual body weight, despite limited dosing information for obese patients. Studies report alterations in daptomycin pharmacokinetics and creatine phosphokinase elevations associated with higher weight-based doses required for obese patients. Limited information regarding clinical outcomes with alternative daptomycin dosing strategies in obesity exists. Objective: This study evaluates equivalency of clinical and safety outcomes in obese patients with daptomycin dosed on adjusted body weight Methods: This retrospective, single center study compared equivalency of outcomes with two one-sided tests in patients with body mass index ⩾30 kg/m Results: A total of 667 patients were screened for inclusion; 101 patients were analyzed with 50 in the actual body weight cohort and 51 in the adjusted body weight cohort. Conclusion: The two daptomycin dosing cohorts were statistically equivalent for both clinical failure and 90-day mortality. More data are needed to assess outcomes with higher (⩾8 mg/kg/day) daptomycin doses in this patient population.
Language	English
Publishing date	2019-01-30
Publishing country	England
Document type	Journal Article
ZDB-ID	2728410-4
ISSN	2049-937X ; 2049-9361
ISSN (online)	2049-937X
ISSN	2049-9361
DOI	10.1177/2049936118820230
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Aggressive treatment of early rheumatoid arthritis: recognizing the window of opportunity and treating to target goals.

Resman-Targoff, Beth H / Cicero, Marco P

The American journal of managed care

2009 Volume 16, Issue 9 Suppl, Page(s) S249–58

Abstract: Evidence supports the use of aggressive therapy for patients with early rheumatoid arthritis (RA). Clinical outcomes in patients with early RA can improve with a treat-to-target approach that sets the goal at disease remission. The current selection of ... ...

Abstract	Evidence supports the use of aggressive therapy for patients with early rheumatoid arthritis (RA). Clinical outcomes in patients with early RA can improve with a treat-to-target approach that sets the goal at disease remission. The current selection of antirheumatic therapies, including conventional and biologic disease-modifying antirheumatic drugs (DMARDs), has made disease remission a realistic target for patients with early RA. The challenge is selecting the optimal antirheumatic drug or combination of drugs for initial and subsequent therapy to balance the clinical benefits, risks, and economic considerations. In some cases, the use of biologic agents as part of the treatment regimen has shown superior results compared with conventional DMARDs alone in halting the progression of disease, especially in reducing radiographic damage. However, the use of biologic agents as initial therapy is challenged by cost-effectiveness analyses, which favor the use of conventional DMARDs. The use of biologic agents may be justified in certain patients with poor prognostic factors or those who experience an inadequate response to conventional DMARDs as a means to slow or halt disease progression and its associated disability. In these cases, the higher cost of treatment with biologic agents may be offset by decreased societal costs, such as lost work productivity, and increased health-related quality of life. Further research is needed to understand optimal strategies for balancing costs, benefits, and risks of antirheumatic drugs. Some key questions are (1) when biologic agents are appropriate for initial therapy, and (2) when to conclude that response to conventional DMARDs is inadequate and biologic agents should be initiated.
MeSH term(s)	Antirheumatic Agents/administration & dosage ; Antirheumatic Agents/economics ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Cost-Benefit Analysis ; Disease Progression ; Humans ; Remission Induction ; Risk Assessment ; Time Factors
Chemical Substances	Antirheumatic Agents
Language	English
Publishing date	2009-06-01
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2035781-3
ISSN	1936-2692 ; 1088-0224 ; 1096-1860
ISSN (online)	1936-2692
ISSN	1088-0224 ; 1096-1860
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5353: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 86: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?.

Chen, Judy T / Pucino, Frank / Resman-Targoff, Beth H

Journal of pain & palliative care pharmacotherapy

2006 Volume 20, Issue 4, Page(s) 11–32

Abstract: Nonsteroidal anti-inflammatory drugs (NSAIDs) are extensively used worldwide. However, associated adverse gastrointestinal effects (NSAID gastropathy) such as bleeding, perforation and obstruction result in considerable morbidity, mortality, and expense. ...

Abstract	Nonsteroidal anti-inflammatory drugs (NSAIDs) are extensively used worldwide. However, associated adverse gastrointestinal effects (NSAID gastropathy) such as bleeding, perforation and obstruction result in considerable morbidity, mortality, and expense. Although it is essential to employ gastroprotective strategies to minimize these complications in patients at risk, controversy remains on whether celecoxib alone or a non-selective NSAID in conjunction with a proton-pump inhibitor (PPI) is a superior choice. Recent concerns regarding potential cardiovascular toxicities associated with cox-2 selective inhibitors may favor non-selective NSAID/PPI co-therapy as the preferred choice. Concomitant use of low-dose aspirin with any NSAID increases the risk of gastrointestinal complications and diminishes the improved gastrointestinal safety profile of celecoxib; whereas use of ibuprofen plus PPI regimens may negate aspirin's antiplatelet benefits. Evidence shows that concurrent use of a non-selective NSAID (such as naproxen) plus a PPI is as effective in preventing NSAID gastropathy as celecoxib, and may be more cost-effective. Patients failing or intolerant to this therapy would be candidates for celecoxib at the lowest effective dose for the shortest duration of time. Potential benefits from using low-dose celecoxib with a PPI in patients previously experiencing bleeding ulcers while taking NSAIDs remains to be proven. An evidence-based debate is presented to assist clinicians with the difficult decision-making process of preventing NSAID gastropathy while minimizing other complications.
MeSH term(s)	Aged ; Anti-Inflammatory Agents, Non-Steroidal/adverse effects ; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Aspirin/adverse effects ; Celecoxib ; Cyclooxygenase Inhibitors/adverse effects ; Cyclooxygenase Inhibitors/therapeutic use ; Decision Making ; Drug Synergism ; Evidence-Based Medicine ; Humans ; Middle Aged ; Myocardial Infarction/chemically induced ; Myocardial Infarction/mortality ; Proton Pump Inhibitors ; Pyrazoles/adverse effects ; Pyrazoles/economics ; Pyrazoles/therapeutic use ; Randomized Controlled Trials as Topic ; Stomach Diseases/chemically induced ; Stomach Diseases/economics ; Stomach Diseases/prevention & control ; Sulfonamides/adverse effects ; Sulfonamides/economics ; Sulfonamides/therapeutic use
Chemical Substances	Anti-Inflammatory Agents, Non-Steroidal ; Cyclooxygenase Inhibitors ; Proton Pump Inhibitors ; Pyrazoles ; Sulfonamides ; Celecoxib (JCX84Q7J1L) ; Aspirin (R16CO5Y76E)
Language	English
Publishing date	2006
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2078852-6
ISSN	1536-0288
ISSN	1536-0288
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2463: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Improving rheumatoid arthritis outcomes: how do we get there?

Brown, J Richard / Marra, Carlo / Pucino, Frank / Resman-Targoff, Beth H

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

2006 Volume 63, Issue 18 Suppl 4, Page(s) S42–4

MeSH term(s)	Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Humans ; Treatment Outcome ; Tumor Necrosis Factor-alpha/antagonists & inhibitors
Chemical Substances	Antirheumatic Agents ; Tumor Necrosis Factor-alpha
Language	English
Publishing date	2006-09-05
Publishing country	England
Document type	Clinical Conference ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1224627-x
ISSN	1079-2082
ISSN	1079-2082
DOI	10.2146/ajhp060366
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 419: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Ensuring quality experiential education.

Haase, Krystal K / Smythe, Maureen A / Orlando, Patricia L / Resman-Targoff, Beth H / Smith, Lisa S

Pharmacotherapy

2008 Volume 28, Issue 12, Page(s) 1548–1551

MeSH term(s)	Curriculum/standards ; Education, Pharmacy/standards ; Educational Measurement/methods ; Educational Measurement/standards ; Health Knowledge, Attitudes, Practice ; Humans ; Pharmacology, Clinical/education ; Pharmacology, Clinical/organization & administration ; Pharmacology, Clinical/standards ; Preceptorship/standards ; Societies, Pharmaceutical/organization & administration ; Societies, Pharmaceutical/standards ; United States
Language	English
Publishing date	2008-12
Publishing country	United States
Document type	Journal Article
ZDB-ID	603158-4
ISSN	1875-9114 ; 0277-0008
ISSN (online)	1875-9114
ISSN	0277-0008
DOI	10.1592/phco.28.12.1548
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1738: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 585: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito